{"entity":{"id":"nct05440786","kind":"trial","name":"CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma","aka":[],"tldr":"A phase 2 trial of Abemaciclib and Temozolomide in ewing sarcoma, run by Eli Lilly and Company, active and no longer recruiting.","summary":"CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma is a phase 2 interventional study registered as NCT05440786 by Eli Lilly and Company, with 46 participants enrolled, started 2022-09-20 and due to reach its primary completion in 2025-01-15. Interventions recorded: Abemaciclib, Irinotecan and Temozolomide. Results have been posted on the registry.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05440786","url":"https://clinicaltrials.gov/study/NCT05440786"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ewing-sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["abemaciclib","temozolomide"],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05440786","phase":"2","setting":"A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing's Sarcoma","sponsor":"Eli Lilly and Company","enrolled":46,"outcomes":[]},"route":"/trials/nct05440786/","neighbours":{"cancer":[{"id":"ewing-sarcoma","kind":"cancer","name":"Ewing sarcoma","route":"/cancers/ewing-sarcoma/"}],"drug":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}]}}